@Article{,
AUTHOR = {Joelle Hamilton},
TITLE = {Using darolutamide in advanced prostate cancer: How I Do It},
JOURNAL = {Canadian Journal of Urology},
VOLUME = {28},
YEAR = {2021},
NUMBER = {3},
PAGES = {10673--10677},
URL = {http://www.techscience.com/CJU/v28n3/60313},
ISSN = {1488-5581},
ABSTRACT = {Darolutamide is a nonsteroidal androgen inhibitor FDA 
approved for the treatment of castration-resistant nonmetastatic prostate cancer (nmCRPC). After decades 
of offering androgen deprivation therapy (ADT) alone 
or first-generation androgen receptor blockers for 
patients whose PSA was rising despite castrate levels 
of testosterone, there are now three different treatment options to add to ADT. These include apalutamide 
approved in February 2018, enzalutamide FDA approved 
in June 2018, and darolutamide approved July 2019. Each 
of these androgen receptor pathway blockers, when added 
to ADT or surgical orchiectomy, prolongs metastasis-free-survival (MFS) and median survival (MS). This paper 
focuses on the use of the newest approved agent in this 
class, darololutmide.},
DOI = {}
}